Litigation Details for Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc. (Fed. Cir. 2017)

Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc. (Fed. Cir. 2017)

Docket		Date Filed	2017-01-17
Court	Court of Appeals for the Federal Circuit	Date Terminated	2018-05-02
Cause		Assigned To
Jury Demand		Referred To
Patents	8,859,623
Link to Docket	External link to docket

Details for Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc. (Fed. Cir. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-01-17				External link to document
2017-01-16	25	Response/Opposition to a Motion or Petition	Paragon’s application issued as U.S. Patent No. 8,859,623 in October 2014, and it does not expire…immediate threat of a patent infringement suit on the ’623 patent. The Patent Office instituted …the Patent Office’s decision here will have in future patent infringement litigation. The Patent Act …APPEAL FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE, PATENT TRIAL AND APPEAL BOARD IN…address the new patent application filing” by Paragon that eventually became the ’623 patent. Ex. 1 ¶ 9;	External link to document

Altaire Pharmaceuticals v. Paragon Bioteck, Inc. | Federal Circuit Case No. 17-1487

Last updated: August 8, 2026

Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc., No. 17-1487, was a Federal Circuit appeal concerning declaratory-judgment jurisdiction in a Hatch-Waxman patent dispute over ophthalmic pharmaceutical products. The court held that Altaire had an Article III controversy with Paragon despite Paragon's covenant not to sue. The decision addressed jurisdiction, not the ultimate validity or infringement of Paragon's patents. [1]

The ruling is important for generic-drug companies because it confirms that a patent owner cannot necessarily eliminate declaratory-judgment jurisdiction by issuing a narrowly framed covenant not to sue after creating a credible patent dispute.

What did Altaire Pharmaceuticals v. Paragon Bioteck concern?

The dispute involved ophthalmic pharmaceutical products manufactured by Altaire and marketed or developed by Paragon. Altaire sought a declaration that its products did not infringe Paragon's patent rights or that the asserted patent claims were invalid.

Paragon argued that no justiciable controversy remained because it had provided Altaire with a covenant not to sue. The U.S. District Court for the District of Delaware dismissed Altaire's declaratory-judgment action for lack of subject-matter jurisdiction.

The Federal Circuit reversed and remanded. It concluded that the covenant did not eliminate the reasonable possibility of future enforcement activity against Altaire's products.

Case identification

Item	Detail
Case	Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc.
Federal Circuit docket	17-1487
Court	U.S. Court of Appeals for the Federal Circuit
Decision date	May 11, 2018
Citation	889 F.3d 1274 (Fed. Cir. 2018)
Lower court	U.S. District Court for the District of Delaware
Primary issue	Article III declaratory-judgment jurisdiction
Disposition	District-court dismissal reversed and remanded
Merits ruling	None on patent validity or infringement

What was the Federal Circuit’s holding?

The Federal Circuit held that Altaire had established an actual controversy sufficient for declaratory-judgment jurisdiction.

The court applied the Supreme Court’s standard from MedImmune, Inc. v. Genentech, Inc., under which jurisdiction exists when the facts show a substantial controversy between parties with adverse legal interests that is sufficiently immediate and real. [2]

The Federal Circuit found that the dispute was concrete because:

1. Paragon had asserted patent rights against Altaire’s product activity.
2. Altaire had taken meaningful steps toward commercial activity involving the relevant ophthalmic products.
3. The parties’ conduct showed adverse legal interests.
4. Paragon’s covenant did not eliminate every plausible future infringement dispute.

The court rejected the view that the covenant automatically ended the controversy. Its scope and practical effect had to be examined against Altaire’s products, future product changes, and the parties’ broader commercial relationship.

Why did the covenant not to sue fail to eliminate jurisdiction?

A covenant not to sue can defeat declaratory-judgment jurisdiction if it is sufficiently broad and unconditional. The relevant question is whether the covenant removes any reasonable basis for the patent owner to pursue infringement claims against the accused party.

The Federal Circuit concluded that Paragon’s covenant was not broad enough to resolve the entire dispute. The covenant was tied to particular products or product configurations and did not necessarily cover future versions, modified formulations, or other commercially relevant activity.

Scope of the covenant

The court focused on the difference between:

• A complete commitment not to enforce the patent against the defendant for all reasonably foreseeable conduct; and
• A limited promise covering only a specified product or formulation.

A narrow covenant may leave a live controversy where the accused party has continuing commercial plans or may make changes that fall outside the covenant’s terms.

The decision therefore treated the covenant as a factual and legal instrument that had to be interpreted in context. A patent owner cannot rely on a covenant’s existence alone if its language leaves material enforcement risk unresolved.

How did the case apply to Hatch-Waxman litigation?

The case arose in the context of pharmaceutical products and ANDA-related patent disputes, but the Federal Circuit’s decision was principally about declaratory-judgment jurisdiction rather than the merits of a statutory patent-infringement claim under 35 U.S.C. § 271(e)(2).

ANDA implications

In a conventional Hatch-Waxman dispute, a generic applicant may trigger litigation by filing an ANDA containing a Paragraph IV certification. The NDA holder can then bring an infringement action under Section 271(e)(2), potentially triggering a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

Altaire is relevant where the patent owner has not provided a complete resolution of the patent dispute, yet the generic or contract manufacturer faces a credible threat of enforcement. The decision supports jurisdiction where:

• The company has taken concrete steps toward marketing;
• The patent owner has asserted or threatened enforcement;
• The product is sufficiently defined for an infringement analysis; and
• The covenant not to sue does not cover the full range of relevant conduct.

The decision does not create a separate generic-entry right. It allows the dispute to proceed in federal court so that the parties can litigate the underlying patent issues.

Did the Federal Circuit rule on patent validity or infringement?

No. The Federal Circuit did not determine whether Altaire’s products infringed Paragon’s patents. It also did not hold that the patents were invalid, unenforceable, or commercially weak.

The decision resolved only the threshold question of whether Altaire’s declaratory-judgment action could proceed. The district court’s dismissal prevented a merits determination. After reversal, the case was remanded for further proceedings.

Issues left unresolved

The opinion did not establish:

• The proper construction of the asserted claims;
• Whether Altaire’s ophthalmic formulations practiced those claims;
• Whether Paragon’s patent claims were anticipated or obvious;
• Whether the patents satisfied written-description or enablement requirements;
• Whether any patent was listed in the FDA Orange Book;
• Whether Altaire had a right to launch before patent expiration; or
• Whether the parties reached a settlement governing market entry.

Those questions required separate proceedings or subsequent resolution.

What was the litigation timeline?

Date	Event
Before 2017	Altaire and Paragon developed conflicting positions concerning Altaire’s ophthalmic products and Paragon’s patent rights.
2017	Altaire pursued declaratory relief in the District of Delaware.
Before Federal Circuit appeal	Paragon issued a covenant not to sue, and the district court dismissed for lack of Article III jurisdiction.
May 11, 2018	Federal Circuit reversed the dismissal in No. 17-1487.
After remand	The district court was required to address the dispute under the Federal Circuit’s jurisdictional ruling.

The Federal Circuit opinion is the key reported decision. The appeal itself did not establish a final generic launch date or commercial settlement.

What does the case mean for patent litigation strategy?

The decision has practical implications for both patent owners and generic manufacturers.

Implications for patent owners

A covenant intended to eliminate jurisdiction should be drafted broadly enough to cover all relevant products and foreseeable conduct. Narrow language can leave the patent owner exposed to a declaratory-judgment action.

A patent owner also should avoid conduct that creates a continuing controversy while arguing that no controversy exists. Patent assertions, licensing demands, product-specific threats, and communications concerning future enforcement can support jurisdiction even after a covenant is issued.

Implications for generic and contract manufacturers

A company seeking declaratory relief should document concrete commercial activity. Relevant evidence may include:

• Product development;
• Manufacturing activity;
• Regulatory filings;
• Commercial supply agreements;
• Planned launch activity;
• Patent-clearance analysis; and
• Communications showing a credible threat of enforcement.

Altaire confirms that a company does not need to wait for an infringement complaint if the dispute is sufficiently immediate and the patent owner’s position creates real commercial exposure.

What was the Orange Book status of the patents?

The reported Federal Circuit decision does not establish a definitive Orange Book listing, patent expiration date, or regulatory exclusivity period for the patents at issue.

The case should not be treated as an Orange Book determination. A patent’s inclusion in the FDA Orange Book depends on the NDA holder’s listing submission and FDA publication. Orange Book listing also does not establish patent validity or guarantee enforcement against every competing product. [3]

For commercial planning, the case therefore provides a jurisdictional precedent rather than a reliable patent-expiry or launch-date analysis.

Did the case involve Paragraph IV challenges?

The case was connected to the pharmaceutical patent framework, but the Federal Circuit’s reported decision did not decide the merits of a Paragraph IV certification.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. It can create a statutory cause of action under Section 271(e)(2) when an ANDA is filed. The Altaire decision instead addressed whether the parties’ broader dispute was sufficiently concrete for declaratory relief.

The distinction matters. A declaratory-judgment ruling does not substitute for:

• A completed ANDA filing;
• A valid Paragraph IV notice;
• A Section 271(e)(2) infringement action;
• A final judgment on patent validity; or
• A negotiated launch settlement.

Did Altaire create biosimilar risk?

No. Altaire involved small-molecule ophthalmic pharmaceutical products, not a biologic licensed under the Public Health Service Act.

The case has no direct biosimilar relevance under the Biologics Price Competition and Innovation Act. Its broader jurisdictional reasoning may be cited in other pharmaceutical disputes, but it does not affect biosimilar interchangeability, patent dance procedures, or biologic exclusivity.

What was the commercial significance of the decision?

The decision reduced the ability of a patent owner to end a live product dispute through a limited covenant not to sue. For generic manufacturers, that can improve access to early judicial review of patent risk before substantial launch investment.

The ruling did not itself authorize market entry. Commercial exposure remained dependent on:

• The scope of Paragon’s patents;
• The final infringement analysis;
• Any FDA approval status;
• Potential patent-term adjustments or extensions;
• Other listed or unlisted patent rights;
• Contractual obligations between the parties; and
• Any later settlement or judgment.

No revenue amount, product-specific market-share figure, or launch date was established by the Federal Circuit opinion.

How strong was the Paragon patent estate after Altaire?

The opinion does not support a merits-based ranking of Paragon’s patent estate.

The estate had enough practical force to create a justiciable controversy, but jurisdictional strength is not the same as patent strength. The Federal Circuit did not test the claims against prior art or assess their enforceability.

A proper patent-strength analysis would require review of:

• The asserted patent claims;
• Patent-family members;
• Continuation and divisional filings;
• Patent-term adjustment;
• Orange Book listings;
• Prosecution-history estoppel;
• Relevant prior art;
• Claim construction;
• Product composition and manufacturing records; and
• Later district-court or Federal Circuit decisions.

Key Takeaways

• Altaire Pharmaceuticals v. Paragon Bioteck, No. 17-1487, was a Federal Circuit jurisdiction decision.
• The court reversed dismissal of Altaire’s declaratory-judgment action.
• Paragon’s covenant not to sue did not eliminate the entire controversy.
• The decision relied on the MedImmune standard for an actual and immediate controversy.
• The court did not decide patent infringement, invalidity, enforceability, patent expiration, or generic launch timing.
• The case is relevant to Hatch-Waxman strategy but is not a merits ruling on a Paragraph IV challenge.
• It involved small-molecule ophthalmic products, not biosimilars.
• The ruling favors early judicial review where a patent owner’s covenant leaves meaningful enforcement risk unresolved.

FAQs About Altaire Pharmaceuticals v. Paragon Bioteck

What Federal Circuit precedent controls declaratory jurisdiction in Altaire?

The court applied MedImmune’s substantial-controversy standard. The parties must have adverse legal interests and a dispute that is immediate and real.

Did Paragon’s covenant not to sue permanently protect Altaire?

No. The Federal Circuit held that the covenant did not necessarily cover all relevant future conduct, products, or formulations.

Did Altaire receive permission to launch its ophthalmic product?

No. The decision restored jurisdiction but did not grant marketing authorization or determine that Altaire’s product was noninfringing.

Did Altaire invalidate Paragon’s patents?

No. The Federal Circuit issued no holding on anticipation, obviousness, written description, enablement, infringement, or enforceability.

Can Altaire be cited in later generic-drug declaratory actions?

Yes. The decision supports jurisdiction where a generic or manufacturer has taken concrete commercial steps and the patent owner’s enforcement position remains materially adverse despite a limited covenant.

References

1. U.S. Court of Appeals for the Federal Circuit. (2018). Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc., 889 F.3d 1274 (Fed. Cir. 2018).

2. U.S. Supreme Court. (2007). MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.